Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which ...

Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Vertex Pharmaceuticals (NASDAQ ... offering several treatments known as CFTR modulators. These products work by correcting a faulty protein that causes symptoms of the disease.

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corp. (TM) and Vertex Pharmaceuticals Inc ... driven by cost reductions and a ...

Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new ... is expected to become a multi-billion dollar product if approved. It works by blocking pain signals at their origin before they ...

Vertex Pharmaceuticals Inc. notched two FDA victories ... blockbuster CF drug, helping drive its product revenue to $9.87 billion last year. Alyftrek is approved for CF patients 6 years and ...

Vertex Pharmaceuticals Inc. will work with a Watertown ... milestones related to sickle cell disease and beta thalassemia products. Plus, Orna could get up to $365 million in additional option ...